T1	Participants 296 362	101 patients with high-risk breast cancer after surgical resection
T2	Participants 265 294	January 2004 to December 2006
T3	Participants 468 620	Each patient received 6 cycles of chemotherapy with intravenous administration of paclitaxel (175 mg/m2, on D3) and epirubicin (60 mg/m2, on Dl and D2).
T4	Participants 1254 1312	Ninety-eight patients completed the chemotherapy as planed
T5	Participants 621 735	The dose-dense group had repeated treatment every two weeks, while the regular group repeated it every three weeks
